Neuropatía autonómica diabética: manifestaciones clínicas poco conocidas
DOI:
https://doi.org/10.47196/diab.v52i2.113Palabras clave:
diabetes, neuropatía autonómica, cardiovascular, gastrointestinal, disfunción vesicalResumen
La neuropatía crónica es la complicación más prevalente de la diabetes. De las distintas formas de neuropatía diabética, la polineuropatía distal y simétrica y la neuropatía autonómica, particularmente la neuropatía autonómica cardíaca, son las más estudiadas y en ocasiones son asintomáticas.
Los pacientes con prediabetes también pueden desarrollar neuropatías similares a la neuropatía diabética. La prevención es un componente clave en la atención de estas complicaciones.
La neuropatía autonómica diabética afecta varios órganos y sistemas de la economía. Nuestro objetivo es describir aquellas manifestaciones clínicas poco conocidas y en consecuencia poco tenidas en cuenta, que afectan el sistema cardiovascular, el gastrointestinal y el compromiso vesical.
Citas
- Ziegler D, Zentai CP, Perz S, et al.; KORA Study Group. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008; 31:556-561.
- Pop-Busui R, Feldman EL, Malik RA, Boulton AJ, Bril V, Freeman R, Sosenko JM, Ziegler D. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40:136-154.
- Jin HY, Baek HS, Park TS. Morphologic changes in autonomic nerves in diabetic autonomic neuropathy. Diabetes Metab J 2015 Dec; 39(6):461-467. English. Review Published online De-cember 11, 2015. https://doi.org/10.4093/dmj.2015.39.6.461
- Actualización en disfunción sexual en pacientes diabéticos. Comité de Neuropatía Diabética de la Sociedad Argentina de Diabetes. Rev Soc Arg Diabetes 2013; 1: 29-39
- Vinik A, Erbas T, Casellini CM. Diabetic cardiac autonomic neu¬ropathy, inflammation and cardiovascular disease. J Diabetes Investig 2013 Jan 29; 4(1): 4-18.
- Pop-Busui R, Cleary PA, Braffett BH, et al.; DCCT/EDIC Research Group. Association between cardiovascular autonomic neuro¬pathy and left ventricular dysfunction: DCCT/EDIC study (Dia¬betes Control and Complications Trial/ Epidemiology of Diabe¬tes Interventions and Complications). J Am Coll Cardiol 2013; 61:447-454.
- Maser RE, Mitchell BD, Vinik AI, et al. The association between cardiovascular autonomic neuropathy and mortality in indi¬viduals with diabetes: a meta-analysis. Diabetes Care 2003; 26:1895-1901.
- Pop-Busui R, Evans GW, Gerstein HC, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Con¬trol Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33:1578-1584.
- Young LH, Wackers FJ, Chyun DA, et al.; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009; 301:1547-1555.
- Vinik A. Diabetic cardiovascular autonomic neuropathy. Circu¬lation 2007; 115:387-397.
- Stewart JM, et al. Clinical and physiological effects of an acute alpna-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance. Circulation 2002; 106, 2946-2954.
- Raj SR. Renin-aldosterone paradox and perturbed blood volu¬me regulation underlying postural tachycardia syndrome. Circulation 2005; 111:1574-1582.
- Stewart JL. Increased plasma angiotensin II in postural tachy¬cardia syndrome (POTS) is related to reduced blood flow and blood volumen. Clinical Science 2006; 110, 255-263.
- Didangelos TP. Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy. Diabetes Care 2003; 26:1955-1960.
- Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043-1065.
- Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 2010; 33:434-441.
- Pop-Busui R, Low PA, Waberski BH, et al.; DCCT/EDIC Research Group. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009; 119:2886-2893.
- Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004; 27:2942-2947.
- Ziegler D, Keller J, Maier C, et al.; German Diabetes Association. Diabetic neuropathy. Exp Clin Endocrinol Diabetes 2014;122: 406-415.
- Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med 2008; 358:615-624.
- Spallone V, Bellavere F, Scionti L, et al.; Diabetic Neuropathy Study Group of the Italian Society of Diabetology. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovasc Dis 2011; 21:69-78.
- Low PA, Gilden JL, Freeman R, et al.; Midodrine Study Group. Efficacy of midodrinevs placebo in neurogenic orthostatic hypotension. A randomized, doubleblind multicenter study. JAMA 1997; 277:1046-1051.
- Low PA, Tomalia VA. Orthostatic hypotension: mechanisms, causes, management. J Clin Neurol 2015; 11:220-226.
- Folwaczny C, Riepl R, Tschöp M, et al.; Gastrointestinal in volvement in patients with diabetes mellitus: Part I (first of two parts). Epidemiology, pathophysiology, clinical findings. Z Gastroenterol 1999; 37: 803-815.
- Zhao J, Frøkjær JB, Drewes AM, et al. Upper gastrointestinal sensory-motor dysfunction in diabetes mellitus. World J Gastroenterol 2006 May 14; 12(18): 2846-2857. www.nature.com/clinicalpractice/gasthep.
- Sellin J, Chang E. Therapy Insight: gastrointestinal complications of diabetes pathophysiology and management. Nature Clinical Practice Gastroenterologic & Hepatologis 2008; 5 (3): 162-171.
- Tsai SC, Kao CH, Pan DY, et al. Effects oforal erythromycin on esophageal motility in patients with noninsulin-dependent diabetes mellitus. The Kaohsiung Journal of Medical Sciences 1995; 11: 430-435.
- Annese V, Bassotti G, Caruso N, et al. Gastrointestinal motor dysfunction, symptoms, and neuropathy in noninsulindependent (type 2) diabetes mellitus. J Clin Gastroenterol 1999; 29: 171-177.
- Holloway RH, Tippett MD, Horowitz M, et al. Relationship between esophageal motility and transit in patients with type 1 diabetes mellitus. Am J Gastroenterol 1999; 94: 3150-3157.
- Björnsson ES, Urbanavicius V, Eliasson B, Attvall S, Smith U, Abrahamsson H. Effects of hyperglycemia on interdigestive gastrointestinal motility in humans. Scand J Gastroenterol 1994; 29: 1096-1104.
- Samsom M, Jebbink RJ, Akkermans LM, van Berge-Henegouwen GP, Smout AJ. Abnormalities of antroduodenal motility in type I diabetes. Diabetes Care 1996; 19: 21-27.
- Azpiroz F, Malagelada C. Diabetic neuropathy in the gut: pathogenesis and diagnosis. Diabetologia 2016; 59:404-408.
- Yarandi SS, Srinivasan S. Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions. Neurogastroenterol Motil 2014; 26:611-624.
- Malagelada C, Drozdzal M, Seguí S, et al. Classification of functional bowel disorders by objective physiological criteria based on endoluminal image analysis. Am J Physiol Gastroin-test Liver Physiol 2015; 309:G413-G419.
- Malagelada C, De Iorio F, Azpiroz F, et al. New insight into intestinal motor function via non invasive endoluminal image analysis. Gastroenterology 2008; 135:1155–1162
- Frøkjaer JB, Andersen SD, Ejskaer N, et al. Gut sensations in diabetic autonomic neuropathy. Pain 2007; 131:320-329.
- Azpiroz F. Gastrointestinal perception: pathophysiological implications. Neurogastroenterol Motil 2002; 14:229-239.
- Distrutti E, Azpiroz F, Soldevilla A, et al. Gastric wall tension determines perception of gastric distention. Gastroenterology 1999; 116: 1035-1042.
- Sellin J, Chang E. Therapy insight: gastrointestinal complications of diabetes pathophysiology and management. Nature Clinical Practice Gastroenterology & Hepatology 2008; 5 (3): 162-171.
- Camilleri M, Parkman H. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013; 108(1): 18-38.
- Camilleri M, Buéno L, et al. Pharmacologic, pharmacokinetic, and pharmacogenomic. Aspects of functional gastrointestinal disorders. Gastroenterology 2016; 150:1319-1331.
- Poen AC, Felt-Bersma RJ, Van Dongen PA, et al. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999; 13:1493-1497.
- Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15:1745-1751.
- Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15:79-86.
- Camilleri M. Diabetic gastroparesis. N Engl J Med 2007; 356:820-829.
- Panel nacional de expertos sobre la atención de gastroparesia ALAD. Rev ALAD 2017; 7: 9-23
- Camilleri M. Appraisal of medium-and long-term treatment of gastro paresis and chronic intestinal dysmotility. Am J Gastroenterol 1994; 89:1769-1774.
- Abell TL, Bernstein VK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 2006; 18:263-283.
- Pfeiffer A, Holgl B, Kaess H. Effect of ethanol and commonly ingested alcoholic beverages on gastric emptying and gastrointestinal transit. Clin Investig 1992; 70:487-491.
- Sanaka M, Anjiki H, Tsutsumi H, et al. Effect of cigarette smoking on gastric emptying of solids in Japanese smokers: a crossover study using the 13C-octanoic acid breath test. J Gas-troenterol 2005; 40:578-582.
- Scott AM, Kellow JE, Eckersley GM, et al. Cigarette smoking and nicotine delay postprandial mouth-cecum transit time. Dig Dis Sci 1992; 37:1544-1547.
- Cho YK, Choi MG, Park EY, et al. Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry. Dig Dis Sci 2013; 58:1035-1041.
- Owczuk R, Twardowski P, Dylczyk-Sommer A, et al. Influence of promethazine on cardiac repolarisation: a double-blind, midazolam-controlled study. Anaesthesia 2009; 64:609-614. PubMed: 19453313.
- Patanwala AE, Amini R, Hays DP, et al. Antiemetic therapy for nausea and vomiting in the emergency department. J Emerg Med 2010; 39: 330-336. PubMed: 20022195.
- Barrett TW, Di Persio DM, Jenkins CA, et al. A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. Am J Emerg Med 2011; 29:247-255.
- Allen JH, de Moore GM, Heddle R, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004; 53:1566-1570.
- Wang L. Clinical observation on acupuncture treatment in 35 cases of diabetic gastroparesis. J Tradit Chin Med 2004; 24: 163-165. PubMed: 15510787.
- Borgnakke WS, Ylöstalo PV, et al. Effect of periodontal disease on diabetes: systematic review of epidemiologicobservational evidence. J Periodontol 2013; 84:S135-52. Doi:10.1902/jop.2013.1340013.
- Borgnakke WS. Hyperglycemia/diabetes mellitus and periodontal infection adversely affect each other. In: Genco RJ, Williams RC, editors. Periodontal disease and overall health: A clinician’s guide. 2º Ed. Yardley, PA: Professional Audience Communications; 2014, 99-122. Disponible en: Http://www.Colgateprofessional.Com/professionaleducation/articles/periodontal-disease-and-overall-health-a-clinicians-guide-secondedition. Accessed: August 22, 2015.
- Borgnakke W. Does treatment of periodontal disease influence systemicdisease? Dent Clin North Am 2015; 59(4):n/a. Doi:10.1016/j.cden.2015.06.007.
- Borgnakke WS, Chapple IL, Genco RJ, et al. The multi-center randomized controlled trial (RCT) published by the Journal of the American Medical Association (JAMA) on the effect of periodontal therapy onglycated hemoglobin (HbA1c) has fundamental problems. J Evid Based Dent Pract 2014; 14:127-32. Doi:10.1016/j.jebdp.2014.04.017.
- American Diabetes Association. Initial evaluation and diabetes management planning. Diabetes Care 2015; 38:S17-9. Doi:10.2337/dc15-S006.
- Netto FO, Diniz IM, Grossmann SM, et al. Risk factors in burning mouth syndrome: a case-control study based on patient records. Clin Oral Investig 2011; 15: 571-575. PMID: 20440632.
- Lamey PJ, Lamb AB. Prospective study of aetiological factors in burning mouth syndrome. Br Med J (Clin Res Ed) 1988; 296: 1243-1246. PMID: 3133028.
- Yilmaz Z, Renton T, Yiangou Y, et al. Burning mouth syndrome as a trigeminal small fibre neuropathy: increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci 2007; 14: 864-871. PMID: 17582772.
- Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome: differential diagnosis. Dermatol Ther 2002; 15287-291. Doi: 10.1046/j.1529-8019.2002.01535.
- Forssell H, Jaaskelainen S, Tenovuo O, et al. Sensory dysfunction in burning mouth syndrome. Pain 2002 Sep 99; (1-2): 41-7.
- Grushka M, Sessle BJ, Howley TP. Psychophysical assessment of tactile, pain and thermal sensory functions in burning mouth syndrome. Pain 1987 Feb; 28(2):169-84.
- Beneng K, Yilmaz Z, Yiangou Y, et al. Sensory purinergic receptor P2X(3) is elevated in burning mouth syndrome. Int J Oral Maxillofac Surg 2010 Apr 24; 815-819.
- Friedman DI. Topirimate-induced burning mouth syndrome. Headache 2010 Sep; 50(8):1383-5.
- Scala A, Checchi L, Montevecchi M, et al. Update on burning mouth syndrome: overviewand patient management. Crit Rev Oral Biol Med 2003; 14:275-291. PMID: 12907696.
- Eusterman VD. Burning mouth syndrome updated. Chief Editor: Arlen D Meyers Feb 07, 2017.
- Moore PA, Guggenheimer J, Orchard T. Burning mouth syndromeand peripheral neuropathy in patients with type 1 diabetes mellitus. J Diabetes Complicat 2007; 21: 397-402. Doi:10.1016/j.jdiacomp.
- Bajaj S, Prasad S, Gupta A, Singh VB. Oral manifestations in type 2 diabetes and related complications. Indian J Endocrinol Metab 2012;16:777-9. Doi:10.4103/2230-8210.100673.
- Arap A, Siqueira SR, Silva CB, et al. Trigeminal pain and quantitative sensory testing in painful peripheral.diabetic neuropathy. Arch Oral Biol 2010; 55:486-93. Doi:10.1016/j.archoral-bio.2010.03.021.
- Collin HL, Niskanen L, Uusitupa M, et al. Oral symptoms and signs in elderly patients with type 2 diabetes mellitus. A focus on diabetic neuropathy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90 (3):299-305. Doi:10.1067/moe.2000.107536.
- Le Floch JP, Le Lievre G, Verroust J, et al. Factors related to the electric taste threshold in type 1 diabetic patients. Diabet Med 1990; 7:526-31. Doi:10.1111/j.1464-5491.1990.tb01436.x.
- Le Floch JP, Le Lievre G, Labroue M, et al. Early detection of diabetic patients at risk of developing degenerative complications using electric gustometry: a five-year follow-up study. Eur J Med 1992; 1:208-14.
- Abbasi AA. Diabetes: diagnostic and therapeutic significance oftaste impairment. Geriatrics 1981; 36:73-4.
- Stolbova K, Hahn A, Benes B, et al. Gustometry of diabetes mellitus patients and obese patients. Int Tinnitus J 1999; 5:135-40.
- Fomina EI, Pozharitskaia MM, Davydov AL, et al. Changes of gustatory perception inelderly patients with type II sugar diabetes. Surgical section. Russian. Stomatologia (Mosk) 2007; 86:30-4.
- Eusterman VD. Burning mouth syndrome updated. Chief Editor: Arlen D Meyers Feb 07, 2017.
- Miziara I, Chagury A, Vargas C, et al. Therapeutic options in idiopathic burning mouth syndrome: literature review. Int Arch Otorhinolaryngol 2015 Jan; 19 (1):86-9.
- Brown JS, Wessells H, Chancellor MB, et al. Urologic complications of diabetes. Diabetes Care 2005 Jan; 28(1):177-85.
- Kebapci N, Yenilmez A, Efe B, et al. Bladder dysfunction in type 2 diabetic Patients. Neurourol Urodyn 2007; 26(6):814-9.
- Moller CF, Olesen KP. Diabetic cystopathy. IV: Micturition cystourethrography compared with urodynamic investigation. Dan Med Bull 1976 Dec; 23 (6): 291-4.
- Yuan Z, Tang Z, He C, et al. Diabetic cystophaty: a review. J Diabetes 2015 Jul; 7(4):442-7. Doi: 10.1111/1753-0407.12272. Epub 2015 Mar 24. Review.
- Liu G, Daneshgari F. Diabetic bladder dysfunction. Chin Med J (Engl). 2014; 127(7):1357-64. Review.
- Golbidi S, Laher I. Bladder dysfunction in diabetes mellitus. Front Pharmacol 2010 Nov 16; 1:136.
- Peters SL, Schmidt M, Michel MC. Rho kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol Sci 2006; 27, 492-497.
- Tammela L, Briscoe JA, Levin RM, et al. Factors underlying the increased sensitivity to field stimulation of urinary bladder strips from streptozotocin-induced diabetic rats. Br J Pharmacol 1994; 113,195-203.
- Waring JV, Wendt IR. Effects of streptozotocin-induced diabetes mellitus on intracellular calcium and contraction of longitudinal smooth muscle from rat urinary bladder. J Urol 2000; 163, 323-330.
- Changolkar AK, Hypolite JA, Disanto M, et al. Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductase. J Urol 2005; 173, 309-313.
- Daneshgari F, Liu G, Birder L, et al. Diabetic bladder dysfunction: current translational knowledge. J Urol 2009; 182,S18-S26.
- Apodaca G, Kiss S, Ruiz W, et al. Disruption of bladder epithelium barrier function after spinal cord injury. Am J Physiol Renal Physiol 2003; 284, F966-F976.
- Yoshimura N, Chancellor MB, Andersson KE, et al. Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int 2005; 95, 733-738.
- Mamas MA, Reynard JM, Brading AF. Nitric oxide and the lower urinary tract: current concepts, future prospects. Urology 2003; 61, 1079-1085.
- Van Poppel H, Stessens R, Van Damme B, et al. Diabetic cystopathy: neuropathological examination of urinary bladder biopsies. Eur Urol 1998; 15, 128-131.
- Steers WD, Tuttle JB. Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 2006; 2, 101-110.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
